Point/Counterpoint #2: Current Clinical Considerations With Nonoperative Management of Rectal Cancer [0.03%]
rectal癌非手术治疗的当前临床考虑因素
Greeshma Rajeev-Kumar,Rohan R Katipally,Shen Li et al.
Greeshma Rajeev-Kumar et al.
Locally advanced rectal cancer has historically been treated with multimodal therapy consisting of radiation therapy, chemotherapy, and total mesorectal excision. However, recent prospective trials and registry studies have demonstrated sim...
Point/Counterpoint #1: Chemotherapy Alone Is a Sufficient Preoperative Treatment for Rectal cancer [0.03%]
焦点讨论一:化学治疗可作为直肠癌术前的足够治疗手段吗
Abhishek Kumar,Manisha Palta,Jingquan Jia
Abhishek Kumar
For decades, the standard neoadjuvant therapy regimen for locally advanced rectal cancer consisted of chemoradiation, surgical resection, and consideration of adjuvant systemic therapy. Additional data have emerged suggesting neoadjuvant sy...
Kristen Donohue,Alexander Rossi,Matthew P Deek et al.
Kristen Donohue et al.
Although total mesorectal excision (TME) remains the standard of care for rectal cancer, including early-stage T1/T2 rectal adenocarcinoma, local excision may be warranted for these early-stage tumors in a select group of patients who may d...
Erqi L Pollom,Vipul R Sheth,Aaron J Dawes et al.
Erqi L Pollom et al.
The treatment paradigm for rectal cancer has been shifting toward de-escalated approaches to preserve patient quality of life. Historically, the standard treatment in the United States for locally advanced rectal cancer has standardly compr...
Zachary R Chalmers,Hannah J Roberts,Jennifer Y Wo
Zachary R Chalmers
The optimal management of T3N0 rectal cancer is an area of active debate that has withstood multiple decades of research. In this comprehensive review, we delve into the many nuances that come with treating T3N0 rectal cancer, particularly ...
Sonal S Noticewala,Prajnan Das
Sonal S Noticewala
In locally advanced rectal cancer, neoadjuvant treatment has evolved from no preoperative treatment to the addition of radiation and systemic therapy and ultimately total neoadjuvant therapy. Total neoadjuvant therapy is the completion of p...
Daniel T Chang
Daniel T Chang
Radiopharmaceuticals for Cancer Diagnosis and Therapy: New Targets, New Therapies-Alpha-Emitters, Novel Targets [0.03%]
癌症诊断和治疗的放射性药物:新靶点,新疗法-.alpha衰变发射体,新颖靶点
Neil K Taunk,Freddy E Escorcia,Jason S Lewis et al.
Neil K Taunk et al.
Radiopharmaceutical therapy has emerged as a promising approach for the treatment of various cancers. The exploration of novel targets such as tumor-specific antigens, overexpressed receptors, and intracellular biomolecules using antibodies...
Diagnostic and Therapeutic Application of Fibroblast Activation Protein Inhibitors in Oncologic and Nononcologic Diseases [0.03%]
纤维活化蛋白抑制剂在肿瘤和非肿瘤疾病中的诊断和治疗应用
Mariko Nakayama,Thomas A Hope,Ali Salavati
Mariko Nakayama
Fibroblast activation protein inhibitor positron emission tomography (PET) has gained interest for its ability to demonstrate uptake in a diverse range of tumors. Its molecular target, fibroblast activation protein, is expressed in cancer-a...
Bone Metastases [0.03%]
骨转移病灶
Gary J R Cook,Matthew P Thorpe
Gary J R Cook
Bone metastases occur frequently in common malignancies such as breast and prostate cancer. They are responsible for considerable morbidity and skeletal-related events. Fortunately, there are now several systemic, focal, and targeted therap...